Overview
The National Cancer Institute's Office of Cancer Clinical Proteomics Research (OCCPR) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) are proud to announce the 2026 CPTAC Scientific Symposium.
On September 21, 2026, join us to explore the latest breakthroughs in cancer proteogenomics. This year’s symposium highlights current research from CPTAC investigators, focusing on how the integration of large-scale proteomic and genomic data (proteogenomics) is redefining our understanding of cancer biology. While the in-person event is reserved for consortium and NIH members, we invite the public to join us via our virtual platform.
The mission of the NCI's OCCPR is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as CPTAC, partnerships with Federal agencies, and collaborations with other organizations/institutions. By illuminating tumor progression, microenvironments, and immune landscapes, CPTAC’s mission remains clear: to accelerate the translation of molecular findings into clinical solutions. We look forward to sharing these insights with you.
We hope you can join us! Sign up for CPTAC email updates: https://proteomics.cancer.gov/sign-email-updates